{"name":"Mapi Pharma Ltd.","slug":"mapi-pharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cariprazine Depot MTD","genericName":"Cariprazine Depot MTD","slug":"cariprazine-depot-mtd","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GA Depot","genericName":"GA Depot","slug":"ga-depot","indication":"Advanced prostate cancer","status":"phase_3"}]}],"pipeline":[{"name":"Cariprazine Depot MTD","genericName":"Cariprazine Depot MTD","slug":"cariprazine-depot-mtd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GA Depot","genericName":"GA Depot","slug":"ga-depot","phase":"phase_3","mechanism":"GA Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist depot formulation that suppresses luteinizing hormone and follicle-stimulating hormone secretion.","indications":["Advanced prostate cancer","Hormone-responsive breast cancer","Endometriosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPVE0xT0llTTRWS1dORW9POFhVb2poVHRvNG5tWkF6WTlxRVpJbEY3TDdsNXBISTVqeEdmZ2tFSGRxQzhvQURhLXV5MnpvaWR2OG1vb0F4aDFZbmlHZmxBRXBmeGlQWVAzSFJwOWU2R0JaWjFoZVBjeHNrTEpteTYtZXROX3VVUl9fcU1HSV9uc0ZPSTlHS2tSVnJHc3Frb3MyRTNNRFlJekNoUzFoem5NZ2l5REh1a3hHRXNQSjZOamFPZVBPTlFVUmVXY280eEhlNUNlaDJWLXZnR3VuRU9OeDFQY0lpLWNVaUN3YmJzdFIwd1pzdGRIMzFMMUkxX1lKRHdoTlBBcUZPX2lteFF4R0Q5TWNBX29fb3FCVDhNRXl3TXc5bjVEWnBqVDJiOE0wc1hMakZLN01lLTk1UFE?oc=5","date":"2026-02-19","type":"pipeline","source":"GlobeNewswire","summary":"Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer - GlobeNewswire","headline":"Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-03","type":"trial","source":"GlobeNewswire","summary":"Mapi Pharma to Present New Safety and Efficacy Data from - GlobeNewswire","headline":"Mapi Pharma to Present New Safety and Efficacy Data from","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOX3c5UHljTWt0ZWJFNE82QXh4UXBvZDFiR2R1RnlDU1h0aW5fQTJzbHMxUjk2Q2xpM05fcDBYVy1QaEs0a2t2WE9MeUM4eXNSVFcwUlQxUHNBNmpIeTBRMHZWUXRPZHRpRGFhVFU0Mk84X053NmhobEVucDRPSV9fNDUtZXhaY3hRUkRv?oc=5","date":"2026-01-06","type":"deal","source":"Yahoo Finance","summary":"Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration - Yahoo Finance","headline":"Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOX2pReEw4UTJXVWFRMFRmSExFUVIzMTVpRzgteGI2bjNDdUxDLWpDMnJYcjBGMi0ycW1Wd0pudXRmeFdGMlN6aHhpS2NOTFFSdlVISjlleGhZV2VaWW1pX1JOMFZ5ZUM4RVYtWi1WNTJQRXhOMUdJTXJvQ25icThWV1hNdHFHa3dJ?oc=5","date":"2025-09-17","type":"trial","source":"Yahoo Finance","summary":"Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection - Yahoo Finance","headline":"Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOSlZvRWx2eTJMMEJTRm1lVWpDZHctMlhOcDRmWnBEQkZsbDNySm9JSnY4R3BQY2NlbUd6QkFfM3RnMGt2TmxfUElKMXJWek5lWnJtdms1RUEzWWhPOWZiTzc5RHJkVUFURDVrN2Z0S0VsOGY3ZFV1U3hBWXluTnhPMzRwbmItWHg5U2Fnd2NXSmUwdERwNGhTR1BEVDlFYWl1TTZVWnJOci1oWF80NGhpUjBBVVBUN0ZBWG1MdjBsTGloYURvakhwN0ZUaGM1N19HUlRrb3hWaFFFN0VjOERYbUhsMy05Qklmb3UyaE94U0FHSjIxbHowZ3lQRUdYZl9zdjJqU1lRNURRQVhpZUpmeWduSEFVSENwY0FyVFFtUkZVSG9OcmRUeUtreDkzaV9uV2hVQg?oc=5","date":"2025-01-14","type":"pipeline","source":"PR Newswire","summary":"Multiple Sclerosis Market in US to Grow by USD 4.99 Billion from 2025-2029, Driven by a Strong Vendor Pipeline and AI-Powered Market Evolution - Technavio - PR Newswire","headline":"Multiple Sclerosis Market in US to Grow by USD 4.99 Billion from 2025-2029, Driven by a Strong Vendor Pipeline and AI-Po","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOaHF2dUdrbjNIWEwxVHNyMTVWMm9IaFo3NnFCVHhHclF0aF9fSGVmQkJEODVxX3RHRjdNSkNscU9hQXJ0bl9Ga3lWbHktbkJsYlpWQkEtdHZ6ZTJDaHd3aGRTaE9aTkx5eFpEaURZaWZuUkswdGFEUDl1OUczajFUa1NWY2owLWhtZzBpU2tPd1RxMUtNR2llMEZVX1NmRExzWVZ4dG5BeHRMRlNmUXBB?oc=5","date":"2024-03-13","type":"regulatory","source":"Healio","summary":"FDA rejects new drug application for intramuscular MS treatment - Healio","headline":"FDA rejects new drug application for intramuscular MS treatment","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOS0g1eUxZYkVEbkt4ck91WjZnN01IdENEZ3pfSEtKckhHeWgwVXVHVTJ4QkJhNWNfWXdrOGdraTliXzAzMF9KTElEazJ4SGh5cER5NzhrbmMzd2FvZ2Zaa01POWtycUV3ODN5RFYxcmNfRTltZmo2LWtEQk1OdF9fV0VvNERIeU1yTVo5cmNYSjNHTE9tM1VnMV9PNTZnX2VXbDZlWnUxaVZDTGJhV09JMTRvbWRoVTZQc3VscTU3MmdVTXdYU3ljRmVEZ1B6QQ?oc=5","date":"2024-03-11","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Viatris's injection for multiple sclerosis - Reuters","headline":"US FDA declines to approve Viatris's injection for multiple sclerosis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNNTZBX2ZKV3FrQUxEYWhzZTluMFlpcWpyUjFaS0ptMUZGQ3YxRDNWbWlubVIzQ2k3OG9wZGxIMDZESjk0TWhrdkU2RV9COC05LUpEblhVTEh4MHJHaWM2UjcwUDJmemtCRURjeUIzTVpWN3pkYkRjclRvSkx4UzRGbGNZRXoyb2FUSkQ3NTZYZ3ZiRzMyOFhyWVFvb1otb0k?oc=5","date":"2024-03-11","type":"regulatory","source":"NeurologyLive","summary":"FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis - NeurologyLive","headline":"FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1kaHY0S3JVbGdXX2NZVzVLSFRSYzRrRHY1RkI5ZEFkSDUwUGpSZ09mYWgxUUp6TjdEbENGbE1mSmhnNWl6Z09HcHNseFZ0ZUFkeXBGMGtaVXJraHp3VklOdHl2V011MmRP?oc=5","date":"2024-03-11","type":"regulatory","source":"גלובס","summary":"FDA rejects Mapi-Viatris long-acting version of Teva's Copaxone - גלובס","headline":"FDA rejects Mapi-Viatris long-acting version of Teva's Copaxone - גלובס","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOM0dWNFNBSU5DMDdTNVJ1cW4zdW5UZ3RZVWFuS2lWVzd4aTlfS3ExQWtOVnZwR0YyTUptck5xU0Y0Ui1HZk9XOGs1bEJvUTRuUXdUcU8weE55M1UtM1lpN0NwRWMydnEyS3JZaHVoUU9UOW5EMVdwZ3FlMFY1Ym9XVWFucVFFc3dXN1JEeUF1cVJmTk5ub0Vmdkswbno4aUJDZHVvOG1Vb0RkalVUQ1JxbGdYZFhsbHlTbEt3MFU3NlN2anB4VjNRbVZteW5uZHlCaEFDVk1PaUZQc1UyRVBIRE1KbWtVcTktNUhkdk11MFJJQUdvdXI3alVoMy00b2xUZE8zaktIWENFVXE0OGt2dHpvMDdwX0pua3JkRUhzdzBUSFU4QUo0TXdUTFJXQzA?oc=5","date":"2023-08-07","type":"regulatory","source":"PR Newswire","summary":"Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis - PR Newswire","headline":"Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNRm5xNGgtcWhoNE01RGRTN1NlR2hDQm1CX3RVX2sxYnljMTFSQy1nSjZGNjB5MjZqaWQ0YXIxRDZuNDZTS1ZsUDZnRE81MFAxS2lVUm5Fd3c0YUk1VVlLcERCM09kdzZzZkw1ZFJSQUxMU0RVdVNhSzMzcm05QTBNajl1RkY0MXVFY1E?oc=5","date":"2020-06-15","type":"pipeline","source":"Contract Pharma","summary":"Mapi Pharma, Mylan Expand MS Alliance - Contract Pharma","headline":"Mapi Pharma, Mylan Expand MS Alliance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPY09vSUhLaEFhSUhWMEJsQ2U4T0xKZ3h6aUxQRHRsQWo3aWdTdFUzN0JPa0VmSWZRZlJVWnVQTmpqNWhZbzc2SzNJcUxXS3o3UUNNejFnY2NkWHdEbk1EUWF5VjFySVZzcXNDbTBvZzRsVTN6RHQzNWNhdzd3X3NPZGJvVmltVXdqb3VEejBXdzg?oc=5","date":"2019-08-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Mapi Pharma’s Sterile Injectable Production Plant, Jerusalem, Israel - Pharmaceutical Technology","headline":"Mapi Pharma’s Sterile Injectable Production Plant, Jerusalem, Israel","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}